<DOC>
	<DOCNO>NCT00754988</DOCNO>
	<brief_summary>This 4 arm study ass efficacy , safety tolerability taspoglutide compare sitagliptin placebo patient type 2 diabetes mellitus inadequately control metformin . Patients randomize receive taspoglutide ( 10mg weekly 10mg weekly 4 week follow 20mg weekly ) , sitagliptin 100mg daily placebo , ratio 2:2:2:1 , addition continue prestudy metformin treatment . After 24 week treatment , patient active treatment continue treatment patient placebo switch taspoglutide 10mg weekly taspoglutide 20mg weekly ( 4 week taspoglutide 10mg weekly ) . The anticipated time study treatment 2+ year , target sample size 500+ individual .</brief_summary>
	<brief_title>A Study Taspoglutide Versus Sitagliptin Treatment Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin .</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>adult patient , 1875 year age ; type 2 diabetes receive metformin ( &gt; =1500mg/day ) least 12 week ; HbA1c &gt; =7.0 % &lt; =10.0 % screening ; BMI &gt; =25 ( &gt; 23 Asians ) &lt; =45kg/m2 screening ; stable weight +/ 5 % least 12 week prior screen . history type 1 diabetes mellitus acute metabolic diabetic complication ketoacidosis hyperosmolar coma previous 6 month ; evidence clinically significant diabetic complication ; clinically symptomatic gastrointestinal disease ; myocardial infarction , coronary artery bypass surgery , posttransplantation cardiomyopathy stroke within previous 6 month ; know hemoglobinopathy chronic anemia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>